Idiopathic Pulmonary Fibrosis - A New Hope

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2005-08-23

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Idiopathic pulmonary fibrosis is a devastating, relentlessly progressive and lethal disease for which current therapy is minimally effective. However, several promising anti-fibrotic agents, such as Enbrel (etanercept), are now in clinical trials, which may lead to significant improvements in disease survival and create a new high-value indication, estimated to be worth up to $2 billion annually.


Scope

  • Examination of the impact of novel drugs on future treatment, supported by interviews with key opinion leaders
  • Assessment of the trends in epidemiology to 2015, including the impact of changing demographics and improvements in diagnosis
  • Discussion of the challenges to future clinical trial design, including optimization of patient recruitment and inclusion of novel endpoints
  • Case study forecasting the global sales of Enbrel (etanercept) to 2015


    • Report Highlights
    Idiopathic pulmonary fibrosis has a five-year survival rate of 20%, affecting 218,000 people in the global market, of which 60% or 125,000, are diagnosed. The aging of the population, combined with improvements in diagnosis, will result in a 40% increase in the diagnosed patient population to 146,000 by 2015.

    Novel therapies which demonstrate progression-free survival will be initiated at diagnosis rather than limited to those patients with advanced disease, analogous to the treatment of rheumatoid arthritis or a malignancy, and will create an estimated market of up to $2 billion annually.

    Future clinical trials should exclude patients with stable minimal to moderate and end-stage disease to ensure maximum response to therapy. The inclusion of acute exacerbation and pharmacoeconomic endpoints is vital, as is ensuring aggressive treatment with a novel drug that does not exacerbate pulmonary infections.


    Reasons to Purchase

  • Identify the long-term patient potential and market segmentation of Idiopathic pulmonary fibrosis
  • Gain insight into the current challenges and commercial opportunities associated with this devastating disease
  • Explore the strengths and weaknesses associated with compounds in clinical development

    • Table of Contents

    Other users found this report page using the following search terms: ipf Idiopathic Pulmonary Fibrosis respiratory fibrosis pulmonary idiopathic end ipf stage advanced survival rate lung

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.